Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Hutchmed China Ltd (13 HK)
Watchlist
177
Analysis
Industrials
•
Hong Kong
HUTCHMED (China) Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Hutchmed China Ltd
•
25 Jan 2023 08:55
Hutchmed China Ltd (13.HK/HCM.US) - The $1.13B Eye-Catching Deal with Takeda and the New Outlook
HUTCHMED/Takeda $1.13 billion license agreement is very worthy of learning.Together with savolitinib's inclusion in new NRDL,2023 performance...
Xinyao (Criss) Wang
Follow
370 Views
Share
bullish
•
Takeda Pharmaceutical
•
24 Jan 2023 02:32
Takeda Strengthens Oncology Portfolio with HUTCHMED’s Fruquintinib Acquisition
Takeda's exclusive licensing agreement with HUTCHMED for further development and commercialisation of Fruquintinib should help its oncology biz...
Shifara Samsudeen, ACMA, CGMA
Follow
340 Views
Share
bullish
•
Wuxi Biologics
•
16 Jan 2023 19:23
Wuxi Biologics Placement - Lesser Discount than Recent Deals but Still Looks Good
Wuxi Biologics Holdings is looking to raise up to US$513m by selling about 1.3% of Wuxi Biologics (2269 HK). This is the company's 16th placement...
Ethan Aw
Follow
488 Views
Share
bullish
•
Thematic (Sector/Industry)
•
02 Jan 2023 08:55
China Healthcare Weekly (Jan.1) - NRDL Negotiation Turnaround, Pullback of TCM, Biotech Sales System
This year's NRDL negotiation could be “a landmark event” for innovative drug industry.Pullback of TCM may really begin from 23Q2.We analyzed...
Xinyao (Criss) Wang
Follow
440 Views
Share
bearish
•
Thematic (Sector/Industry)
•
26 Dec 2022 08:45
China Healthcare Weekly (Dec.25) - OK Lens VBP, Angelalign, Extraordinary 2022 for Pharmaceuticals
The OK lens VBP in Hebei was the first to release detailed rules. The orthodontic material VBP result would affect Angelalign's outlook. 2022 is an...
Xinyao (Criss) Wang
Follow
566 Views
Share
First
Previous
4
5
6
7
8
9
10
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x